Yeh Y.-C.PEI-JER CHENLai M.-S.2021-07-032021-07-0320130098-7484https://www.scopus.com/inward/record.uri?eid=2-s2.0-84874389116&doi=10.1001%2fjama.2013.571&partnerID=40&md5=89a6d6f6f6947d3b0e885e68990fcc64https://scholars.lib.ntu.edu.tw/handle/123456789/568459[SDGs]SDG3antivirus agent; nucleoside analog; advanced cancer; antiviral therapy; cancer staging; disease association; drug effect; drug efficacy; drug exposure; drug response; hepatitis B; human; letter; liver cell carcinoma; liver resection; observational study; priority journal; recurrent cancer; risk assessment; risk reduction; survival rate; survival time; treatment duration; tumor volume; female; liver cell carcinoma; liver tumor; male; note; pathology; virology; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis B; Humans; Liver Neoplasms; Maleletter10.1001/jama.2013.571234434302-s2.0-84874389116